av中文在线中文亚洲-av中文字幕-av中文字幕不卡无码-av中文字幕潮-av中文字幕潮喷在线-av中文字幕第一

GenFleet Starts First-in-human Phase I Trial of Highly Selective CDK9 Inhibitor

勁方醫藥
May 10, 2021
Share

May 10,2021 (Tianjin, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that the first patient has been dosed in its first-in-human trial of GFH009. As the first highly selective CDK9 inhibitor entering clinical stage in China, GFH009 has been granted with IND approvals by both Chinese and US authorities for the treatment of recurrent/refractory hematological malignancies. 

The primary objective of this study is to evaluate the safety and tolerability of GFH009 among patients with recurrent/refractory hematological malignancies including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and other lymphomas. In addition to characterizing the pharmacokinetic profile of GFH009, the study will also assess the preliminary anti-tumor activities of compound and test specific biomarkers in peripheral blood among patients. 

Preclinical studies have demonstrated that GFH009 is a potent and highly selective small-molecule inhibitor of CDK9 with more than 100 times selectivity over other CDK subtypes.

“We target at recurrent/refractory hematological malignancies in phase I trial based on the properties of CDK9 and data of biomarkers from preclinical studies, expecting to expand the clinical application of CDK inhibitors. Building on the FIH results, we will continuously refine and optimize our clinical development plan of GFH009. As GenFleet's first global multi-center trial, study of GFH009 will remarkably promote our global development of innovative drugs. " said Yu Wang, M.D./Ph.D., Chief Medical Officer of GenFleet Therapeutics.

“GenFleet has been conducting clinical trials of TGF-β R1 inhibitor and RIPK1 inhibitor in China and Australia respectively. It marks another major milestone as we proceed with synchronous enrollment of patients in China and US in the FIH trial of highly selective CDK9 inhibitor. There was no clinical proof of concept for the target of CDK9 when we started the project, which is typical of GenFleet's innovative pipeline that focuses on novel mechanisms.” said Jiong Lan, Ph.D., Chief Executive Officer of GenFleet Therapeutics. 

About GFH009 and CDK9

As a potent and highly selective small molecule CDK9 inhibitor, GFH009 exhibits strong apoptosis-inducing and anti-proliferation activities in a variety of human cell lines and animal models of diseases. It effectively inhibits the growth of tumor in various xenograft models and significantly improves survival of tumor bearing animals. Preclinical data have also suggested the potential anti-tumor effects of GFH009 in combination with BCL-2 inhibitors.

As a family of serine & threonine kinases, cyclin-dependent kinase (CDK) plays an important role in cell cycle regulation and transcription. CDK9 is one of the most potential targets for cancer therapeutics in the CDK family. Compared with non-selective CDK inhibitors, highly selective CDK9 inhibitors are advantageous in avoiding off-target toxicity against other CDK subtypes and reducing the risk of dose-limiting toxicity. Currently, no highly selective CDK9 inhibitors have been authorized with New Drug Application (NDA) approvals on the global market.

主站蜘蛛池模板: 亚洲国产va乱码毛片一级高清三 | 久久精品伊人久久精品 | 亚洲精品嫩草AV在线观看 | 国产亚洲精品在线视频一 | 视频一区视频二区在线观看 | 国产一区二区三区在线免费 | 日本熟妇无码波多野1223 | 国产丝袜无码一区二区视频 | 嫩草精品国产亚洲av高清不卡 | 97无码久久久久中文字幕精品 | 四房色播网址 | 18禁人看免费无遮挡网站不卡 | 无套内谢少妇毛片A片软件 无套内谢少妇毛片A片小说色噜噜 | 国产精品无码一区二区在线观一 | 97人妻无码一区 | 国产aⅴ精品一区二区三区久 | 伊人91 | 国产精东剧天美 | 丁香花色情成人网站 | 无码av毛片一区二区 | 亚洲一区二区欧美日韩 | 高清国产一级毛片国语 | 天天干天天摸天天操 | 国产精品色字幕综合免费一区二区三区 | 丁香五月缴情综合网 | 无码人妻aⅴ一区二区三区a片在线观看 | 亚洲精品一区二区精华液 | 国产一区二区区别:特点与差异剖析 | 无人区在线完整免费 | 国产精品一亚洲av | 免费国产成人高清在线观看网站 | 久久亚洲精品无码A片大香大香 | 人妻洗澡被强伦姧完整国产 | 麻豆激情在线视频 | 精品国产一区二区三区不卡 | 国产午夜福利精品在线观看不卡 | 国产精品国产三级大全在线观看 | 中文字幕一区波多野结衣 | 久久中字 | 国产成人无码aⅴ片在线观看rv | 免费成人在线视频一区二区 |